Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment
- 1 July 1989
- journal article
- research article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 17 (1) , 177-181
- https://doi.org/10.1016/0360-3016(89)90386-6
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans?Cancer Chemotherapy and Pharmacology, 1988
- Chemical modifiers of cancer treatment.Journal of Clinical Oncology, 1988
- Gradient high-performance liquid chromatographic method for simultaneous assay of the radiosensitizers etanidazole (SR 2508) and pimonidazole (Ro 03-8799) in biological materialsJournal of Chromatography B: Biomedical Sciences and Applications, 1987
- Phase I trial of the hypoxic cell radiosensitizer SR-2508: The results of the five to six week drug scheduleInternational Journal of Radiation Oncology*Biology*Physics, 1986
- A Phase I study of the combined hypoxic cell radiosensitisers, Ro 03–8799 and SR 2508: a preliminary report of single-dose toxicity, pharmacokinetics and tumour concentrationsThe British Journal of Radiology, 1986
- Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508International Journal of Radiation Oncology*Biology*Physics, 1984
- SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical useInternational Journal of Radiation Oncology*Biology*Physics, 1981
- Critique of “misonidazole—A drug for trial in radiotherapy and oncology”International Journal of Radiation Oncology*Biology*Physics, 1980